Scilex Holding (SCLX) Enterprise Value (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Enterprise Value of -$149.9 million for Q1 2026, down 2484.9% year-over-year from $6.3 million in Q1 2025, and down 1579.63% quarter-over-quarter from -$8.9 million in Q4 2025.
Scilex Holding (SCLX) Enterprise Value (2020 - 2026) Analysis & Trends
Scilex Holding's Enterprise Value history runs 7 years deep, the most recent figure standing at -$149.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 2484.9% year-over-year to -$149.9 million; the TTM figure through Mar 2026 stood at -$149.9 million (down 2484.9% YoY), while the FY2025 annual figure was -$8.9 million, down 172.8% from the prior year.
- Enterprise Value for Q1 2026 stood at -$149.9 million, down from -$8.9 million in the prior quarter.
- The five-year high for Enterprise Value was -$69922.0 in Q3 2022, with the low at -$149.9 million in Q1 2026.
- The 5-year median for Enterprise Value is -$3.7 million (2025), against an average of -$13.7 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 9607.58% in 2023, then jumped 96.06% in 2024.
- Scilex Holding's Enterprise Value stood at -$2.2 million in 2022, then slumped by 79.53% to -$3.9 million in 2023, then rose by 16.55% to -$3.3 million in 2024, then tumbled by 172.8% to -$8.9 million in 2025, then slumped by 1579.63% to -$149.9 million in 2026.
- Business Quant data shows SCLX's Enterprise Value at -$149.9 million in Q1 2026, -$8.9 million in Q4 2025, and -$3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -114.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -149.92 Mn |
| Dec 31, 2025 | -8.93 Mn |
| Sep 30, 2025 | -3.68 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Mar 31, 2025 | -5.80 Mn |
| Dec 31, 2024 | -3.27 Mn |
| Sep 30, 2024 | -77,000.00 |
| Jun 30, 2024 | -6.89 Mn |
| Mar 31, 2024 | -1.80 Mn |
| Dec 31, 2023 | -3.92 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -34.10 Mn |
| Mar 31, 2023 | -5.10 Mn |
| Dec 31, 2022 | -2.18 Mn |
| Sep 30, 2022 | -69,922.00 |
| Jun 30, 2022 | -351,272.00 |
| Mar 31, 2022 | -250,000.00 |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -115,642.00 |
| Jun 30, 2021 | -257,621.00 |